Scholarlink

<p>Respiratory syncytial virus (RSV) infections also cause severe disease in adults, especially in patients who are older, immunosuppressed or have pulmonary diseases. Patients with rheumatic diseases are particularly at risk due to immunosuppressive therapies or organ involvement of a systemic inflammatory disease. Despite this, RSV has often been underrecognized in adult medicine. The aim of this review is to provide rheumatologists with a concise, clinically relevant update to better assess RSV risk and to promote the informed use of new RSV vaccinations. This is addressed through practical questions on epidemiology, risk assessment, and vaccination, with a focus on patients with rheumatic diseases. The clinical significance of RSV, the efficacy of new vaccines, and available safety data in immunocompromised individuals are summarized. We also explore “off-label” use for high-risk individuals under 60 years of age who are currently excluded from approved indications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RSV in der Rheumatologie: Klinische Relevanz und neue Impfstoffe

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月17日

查看全文
  • Dorothea Miltner,
  • Christoph T. Berger

摘要

Respiratory syncytial virus (RSV) infections also cause severe disease in adults, especially in patients who are older, immunosuppressed or have pulmonary diseases. Patients with rheumatic diseases are particularly at risk due to immunosuppressive therapies or organ involvement of a systemic inflammatory disease. Despite this, RSV has often been underrecognized in adult medicine. The aim of this review is to provide rheumatologists with a concise, clinically relevant update to better assess RSV risk and to promote the informed use of new RSV vaccinations. This is addressed through practical questions on epidemiology, risk assessment, and vaccination, with a focus on patients with rheumatic diseases. The clinical significance of RSV, the efficacy of new vaccines, and available safety data in immunocompromised individuals are summarized. We also explore “off-label” use for high-risk individuals under 60 years of age who are currently excluded from approved indications.